RecruitingNot ApplicableNCT07559201

Theranostic Applications of Radionuclides in Prostate Cancer

ACP3 Targeted -PET/ CT in Prostate Cancer

Sponsor

Guilin Medical University, China

Enrollment

100 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer (Diagnosis)

Summary

The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying standard-of-care imaging (PSMA/FDG PET/CT), ACP3 PET/CT for people with prostate cancer (diagnosis). The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTstandard-of-care imaging (PSMA/FDG PET/CT), ACP3 PET/CT

Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (PSMA/FDG) and ACP3, and undergoes PET/CT imaging within the specified time.